Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2018

View Archived Issues

CBT and Zhejiang Bossan announce collaborate to develop combination cancer treatments

Simple sugar may impair cancer growth in mice

Alunbrig approved in Europe for patients with ALK+ NSCLC previously treated with crizotinib

Melinta Therapeutics granted marketing authorization for Vabomere in Europe

Athenex initiates phase I/II trial of Oraxol in combination with pembrolizumab

First patient dosed in phase II study of omadacycline in acute pyelonephritis

Evelo Biosciences announces plans for first monoclonal microbial oncology product candidate

Phase III CheckMate-451 study of Opdivo with Yervoy in extensive-stage SCLC misses primary endpoint

Acquist Therapeutics presents data for novel dual XO and URAT1 inhibitor RLBN-1127

Glenmark Pharmaceuticals discovers NADPH oxidase inhibitors

Wockhardt describes new antibacterial diazabicyclooctane derivatives

University of California, Oakland, Istituto Italiano di Tecnologia (IIT) patent RhoJ inhibitors

Moderna Therapeutics begins phase I study of mRNA-2752 in advanced malignancies

University of Louisville describes anticancer copper complexes

ViiV Healthcare presents HIV replication inhibitors

ER-INP as novel therapeutic strategy for drug-induced acute liver injury

ET-D5 demonstrates promising in vivo efficacy as potential new anticancer therapy

First-in-human data for MK-4280 alone or in combination with pembrolizumab

FDA clears IND for PBCAR-0191 allogeneic CAR T product candidate

Vertex reports phase III data on VX-659 triple combination regimen for cystic fibrosis

New phase I trial explores nasal administration of foralumab in healthy volunteers

Bile acid receptor implicated in hepatic encephalopathy due to liver cirrhosis

Spark Therapeutics to begin phase I/II study of SPK-8016 gene therapy in hemophilia A

Preclinical evaluation of zifaxaban, an oral inhibitor of factor Xa for thromboembolic diseases

New deep vein thrombosis model allows real-time in vivo imaging

Preclinical results of EAGLE technology targeting glyco-immune checkpoints for cancer treatment

Phase II trial of bemcentinib/pembrolizumab combination in patients with advanced NSCLC and melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...